Capital Health Plan, Inc.

Financial Statements and Supplemental Schedules Statutory Basis of Accounting December 31, 2021 and 2020

Capital Health Plan, Inc. Index

December 31, 2021 and 2020

| | Page(s) |
|---|---------|
| Report of Independent Auditors | 1–3 |
| Statutory Financial Statements | |
| Statements of Admitted Assets, Liabilities and Capital and Surplus | 4 |
| Statements of Revenue and Expenses and Changes in Capital and Surplus | 5 |
| Statements of Cash Flows | 6 |
| Notes to Financial Statements | 7–22 |
| Supplemental Schedules | |
| Summary Investment Schedule | 24 |
| Supplemental Investment Risks Interrogatories | 25–29 |
| Supplemental Schedule of Reinsurance Disclosures | 30-31 |



Report of Independent Auditors

To the Management and Board of Directors of Capital Health Plan, Inc.

Opinions

We have audited the accompanying statutory basis financial statements of Capital Health Plan, Inc. (the "Company"), which comprise the statutory basis statements of admitted assets, liabilities and capital and surplus as of December 31, 2021 and 2020, and the related statutory basis statements of revenue and expenses and changes in capital and surplus, and of cash flows for the years then ended, including the related notes (collectively referred to as the "financial statements").

Unmodified Opinion on Statutory Basis of Accounting

In our opinion, the accompanying financial statements present fairly, in all material respects, the admitted assets, liabilities and capital and surplus of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in accordance with the accounting practices prescribed or permitted by the Florida Office of Insurance Regulation described in Note 2.

Adverse Opinion on U.S. Generally Accepted Accounting Principles

In our opinion, because of the significance of the matter discussed in the Basis for Adverse Opinion on U.S. Generally Accepted Accounting Principles section of our report, the accompanying financial statements do not present fairly, in accordance with accounting principles generally accepted in the United States of America, the financial position of the Company as of December 31, 2021 and 2020, or the results of its operations or its cash flows for the years then ended.

Basis for Opinions

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Basis for Adverse Opinion on U.S. Generally Accepted Accounting Principles

As described in Note 2 to the financial statements, the financial statements are prepared by the Company on the basis of the accounting practices prescribed or permitted by the Florida Office of Insurance Regulation, which is a basis of accounting other than accounting principles generally accepted in the United States of America.

The effects on the financial statements of the variances between the statutory basis of accounting described in Note 2 and accounting principles generally accepted in the United States of America are material.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with the accounting practices prescribed or permitted by the Florida Office of



Insurance Regulation. Management is also responsible for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with US GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the financial statements taken as a whole. The supplemental summary investment schedule, investment risks interrogatories and schedule of reinsurance disclosures (collectively referred to as the "supplemental schedules") of the Company as of December 31, 2021 and for the year then ended are presented to comply with the National Association of Insurance Commissioners' Annual Statement Instructions and Accounting Practices and Procedures Manual and for purposes of additional analysis and are not a required part of the financial statements. The supplemental schedules are the responsibility of



management and were derived from and relate directly to the underlying accounting and other records used to prepare the financial statements. The supplemental schedules have been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplemental schedules are fairly stated, in all material respects, in relation to the financial statements taken as a whole.

Jacksonville, Florida March 31, 2022

Pricewaterhouse Coopera LLP

Capital Health Plan, Inc. Statutory Statements of Admitted Assets, Liabilities and Capital and Surplus December 31, 2021 and 2020

| (in thousands of dollars) | 2021 | 2020 |
|---|--|--|
| Admitted Assets Bonds Common stocks Cash, cash equivalents and short-term investments Real estate investments, net Receivables for securities Total cash and invested assets | \$ 500,574 114,577 12,401 41,200 3,147 671,899 | \$ 465,313 124,268 12,189 42,613 7,268 651,651 |
| Investment income due and accrued Premiums and consideration receivables, net Health care receivables, net Other admitted assets | 2,027 4,996 19,982 5,596 | 2,169 8,395 14,763 5,054 |
| Total admitted assets | \$ 704,500 | \$ 682,032 |
| Liabilities and Capital and Surplus Liabilities Claims unpaid | \$ 71,605 | \$ 69,648 |
| Unpaid claims adjustment expenses Aggregate health policy reserves Premiums received in advance General expenses due or accrued Amount due to affiliates Payable for securities Other liabilities | 670 1,250 13,290 4,451 1,550 10,344 39,330 | 700 5,080 12,020 3,579 1,417 15,178 44,216 |
| Total liabilities | 142,490 | 151,838 |
| Capital and Surplus Unassigned funds (surplus) Total capital and surplus | 562,010 562,010 | 530,194 530,194 |
| Total liabilities and capital and surplus | \$ 704,500 | \$ 682,032 |

Capital Health Plan, Inc.

Statutory Statements of Revenue and Expenses and Changes in Capital and Surplus

Years Ended December 31, 2021 and 2020

| (in thousands of dollars) | | 2020 | | | |
|--|----|---------|----|---------|--|
| Revenue | | | | | |
| Net premium income | \$ | 947,976 | \$ | 907,040 | |
| Fee-for-service | | 2,266 | | 1,882 | |
| Total revenue | | 950,242 | | 908,922 | |
| Expenses | | | | | |
| Hospital and medical expenses | | 898,170 | | 832,828 | |
| Claims adjustment expenses | | 11,314 | | 12,152 | |
| Administrative expenses | | 43,688 | | 40,484 | |
| Assessments and fees | | 294 | | 8,936 | |
| Total underwriting expenses incurred | | 953,466 | | 894,400 | |
| Net underwriting gain | | (3,224) | | 14,522 | |
| Net investment income earned | | 17,479 | | 17,025 | |
| Net realized gains on investments | | 15,593 | | 8,028 | |
| Other income, net | | (184) | | (180) | |
| Net income | | 29,664 | | 39,395 | |
| Capital and surplus | | | | | |
| Beginning of year | | 530,194 | | 486,068 | |
| Change in net unrealized gains on investments | | 5,122 | | 9,374 | |
| Change in nonadmitted assets | | (5,051) | | (3,764) | |
| Change in net assets for postretirement benefits | | 2,081 | | (879) | |
| End of year | \$ | 562,010 | \$ | 530,194 | |

Capital Health Plan, Inc. Statutory Statements of Cash Flows Years Ended December 31, 2021 and 2020

| (in thousands of dollars) | 2021 | 2020 | | |
|---|---------------|------|-----------|--|
| Cash from operations | | | | |
| Premiums collected net of reinsurance | \$ 942,709 | \$ | 916,452 | |
| Net investment income | 21,558 | | 20,419 | |
| Other income | (2,442) | | 150 | |
| Benefit and loss-related payments | (899,836) | | (833,040) | |
| Claims adjustment expenses | (10,868) | | (11,708) | |
| Administrative expenses | (39,772) | | (48,486) | |
| Net cash from operations | 11,349 | | 43,787 | |
| Cash from investments | | | | |
| Proceeds from investments sold or matured or repaid | | | | |
| Bonds | 290,937 | | 341,852 | |
| Common stocks | 34,525 | | 20,005 | |
| Total investment proceeds | 325,462 | | 361,857 | |
| Cost of investments acquired | | | | |
| Bonds | (329,608) | | (380,778) | |
| Common stocks | (5,359) | | (19,597) | |
| Other investments acquired | (1,632) | | (2,595) | |
| Total investments acquired | (336,599) | | (402,970) | |
| Net cash from investments | (11,137) | | (41,113) | |
| Net increase in cash, cash equivalents and short-term investments | 212 | | 2,674 | |
| Cash, cash equivalents and short-term investments | | | | |
| Beginning of year | 12,189 | | 9,515 | |
| End of year | \$ 12,401 | \$ | 12,189 | |

1. Background

Organization

Capital Health Plan, Inc. ("CHP") is a not-for-profit federally qualified and state licensed staff model Health Maintenance Organization ("HMO"), which provides health care services to subscribers in Leon and surrounding counties in Florida.

CHP has an affiliation agreement with Blue Cross and Blue Shield of Florida, Inc., d/b/a Florida Blue, giving Florida Blue majority control of the corporate membership of CHP. Florida Blue is a wholly owned subsidiary of GuideWell Mutual Holding Corporation, a not-for-profit, policyholder owned mutual insurance holding company. The affiliation provides that Florida Blue may supply certain administrative services and products to CHP and also commits Florida Blue to loan CHP operating funds, if necessary.

2. Summary of Significant Accounting Policies

CHP is domiciled in the State of Florida and is required to prepare statutory financial statements in accordance with the *National Association of Insurance Commissioners ("NAIC") Accounting Practices and Procedures Manual,* subject to any deviations prescribed or permitted by the Office of Insurance Regulation of the State of Florida ("OIR"), the basis for statutory accounting practices ("SAP"). Accordingly, these statutory financial statements are not intended to present the financial position and results of operations in conformity with accounting principles generally accepted in the United States of America ("GAAP"). We have prepared the Company's financial statements on the basis that the Company is able to continue as a going concern. There are no conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.

The accounting policies utilized in preparing the statutory financial statements differ in certain respects from those which would have been used if these financial statements were prepared in accordance with GAAP. The most significant differences are:

- Certain assets are designated as "nonadmitted assets" for statutory accounting purposes.
 These nonadmitted assets include certain accounts receivable, health care receivables,
 nonoperating system software, prepaid insurance, and maintenance assets. These
 differences have been charged to capital and surplus.
- For statutory purposes, CHP's bonds, which are comprised of United States of America ("U.S.") Government treasury and agency securities, municipal bonds, corporate bonds, and mortgage and asset backed securities, are primarily reported at amortized cost. For GAAP, such investments are reported at fair value as of the financial statement date.
- The claims unpaid reserve estimates are developed for purposes of the health reserves for the statutory financial statement. These estimates can differ from those reported for GAAP.

A reconciliation of statutory capital and surplus to GAAP net assets as of December 31, 2021 and 2020 is as follows:

| (in thousands of dollars) | 2021 | 2020 |
|--|---------------|---------------|
| Statutory surplus | \$ 562,010 | \$ 530,194 |
| Claims Reserves | - | 750 |
| Unrealized (gains) losses on investments | 4,751 | 20,438 |
| Nonadmitted assets | 26,739 | 21,688 |
| Net assets-GAAP | \$ 593,500 | \$ 573,070 |

A reconciliation of statutory net income to GAAP net income as of December 31, 2021 and 2020 is as follows:

| (in thousands of dollars) | 2021 | 2020 | | | |
|--|--------------|--------------|--|--|--|
| Statutory net income | \$ 29,664 | \$ 39,395 | | | |
| Change in hospital/medical benefit | (750) | (2,750) | | | |
| Change in unrealized gains (losses) on investments | (10,565) | 20,335 | | | |
| Other postretirement benefit changes | 2,081 | (879) | | | |
| Net income-GAAP | \$ 20,430 | \$ 56,101 | | | |

Cash and Cash Equivalents and Short-Term Investments

Cash and cash equivalents consist of cash demand deposits, certificates of deposit, money market funds, and investments with original maturities of 90 days or less from the date of purchase. CHP's management places its cash and cash equivalents with creditworthy financial institutions and thus limits its credit exposure. Short-term investments have a maturity when purchased of less than one year and are reflected at amortized cost which approximates fair value. The carrying amounts of cash and cash equivalents approximate their fair value.

Receivables and Payables for Securities

The amounts receivable or payable for investments with settlements pending result from the sales or purchases of investments made prior to the end of the fiscal year, but settled after the fiscal year-end.

Investments

Bonds are comprised of U.S. Government treasury and agency securities, municipal bonds, corporate bonds, and mortgage-backed and asset—backed securities, and are primarily carried at amortized cost. Amortization of bond premium or discount is calculated using the prospective interest method, taking into consideration specific interest and principal provisions over the life of the bond. Bonds, including loan-backed securities, are stated at the lower of amortized cost or fair value, based upon NAIC designation. Loan-backed securities are stated at amortized cost using the scientific interest method including prepayment assumptions obtained from external data sources. Bonds have a maturity date exceeding one year from the date of purchase. Realized investment gains and losses are calculated on a weighted-average basis of identification and are included in net realized investment gains. Common stocks are comprised of mutual funds and reported at fair market value. Investment income is reported net of investment expenses.

Bonds and common stocks are considered impaired and are written down to fair value through the statutory statements of revenue and expenses and changes in capital and surplus when management expects a decline in value to persist (i.e. the decline is "other-than-temporary"), intends to sell the security prior to recovery, or if it is more likely than not that CHP will be required to sell the security prior to recovery. With respect to securities where the decline in value is determined to be temporary and the security's value is not written down, a subsequent decision may be made to sell that security and realize a loss. If a security's decline in fair value is not expected to be fully recovered prior to the expected time of sale, CHP would record an other-than-temporary impairment in the period in which the decision to sell is made.

Fair Value of Financial Instruments

In accordance with Statements of Statutory Accounting Practices ("SSAP 100") – Fair Value Measurements, which establishes a framework for measuring and reporting fair value, levels are classified based on types of inputs used to measure fair value and are prioritized by the fair value hierarchy established by SSAP 100. Highest priority is given to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and lowest to unobservable inputs (Level 3 measurement). CHP obtains pricing for investments from a single pricing service, Intercontinental Exchange ("ICE") Data Services.

The three levels of the fair value hierarchy defined by SSAP 100 are as follows:

- Level 1 Pricing inputs are based on quoted prices available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.
- Level 2 Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.
- Level 3 Pricing inputs include significant inputs that are generally less observable or unobservable from objective sources and may include internally developed methodologies that result in management's best estimate of fair value from the perspective of a market participant.

The following methods and assumptions were used to determine fair value of each class:

Bonds: Based on CHP's internal price verification procedures and review of fair value methodology documentation provided by independent pricing services, CHP has not historically adjusted the prices obtained from the pricing service. In situations where ICE Data Services does not have multiple observable inputs or the ability to price a given security, a price is obtained from another pricing service or by obtaining nonbinding broker or dealer quotes.

Common Stocks: Fair values are generally designated as Level 1 and are based on net asset value which is determined by the value of the underlying securities which are based on quoted market prices.

Concentration of Credit Risk

Investments in cash demand deposits are held primarily in accounts with major banks which exceed federally insured amounts. Investments in money market accounts are not federally

insured. The financial stability of these institutions and money market accounts are reviewed on a continuous basis. Credit losses are not anticipated. Bonds, including loan–backed securities, are diversified and include investment grade securities that are rated at the time of purchase by nationally recognized statistical rating organizations. These credit ratings are routinely reviewed and holdings are adjusted accordingly.

CHP's potential exposure to subprime lending is limited to investments within its bond investment portfolio which contain securities collateralized by mortgages that may have characteristics of subprime lending. CHP's bond investment policy limits securities that are backed by subprime mortgages. There were no securities backed by subprime mortgages held during the years ended December 31, 2021 and 2020.

CHP has concentration of credit risk with respect to unpaid premiums and business volume. CHP maintains the right to terminate coverage for employer groups and individuals who fail to pay premiums timely. CHP has one customer, the State of Florida, that accounts for 36% of CHP's direct premium income for 2021 and 2020, respectively. CHP has provided health care coverage to State of Florida employees and its retirees for 40 years. CHP has a current contract through 2022 with ability to renew for one additional one (1) year term. While inherently impossible to predict, a loss of the State of Florida contract could have adverse results on CHP operations.

Geographic Concentration Risk

CHP's business is generated within a limited service area. Accordingly, a disruption in membership or revenue within this service area might have a more significant effect on the Company than a more geographically diversified company and could have an adverse impact on CHP's financial condition and operating results.

Property and Equipment Real Estate Investments, net

Real estate investments, net, which include expenditures for significant improvements, are recorded at cost, less accumulated depreciation. Maintenance, repairs, and minor improvements are expensed as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected as other income or expense in the statutory statements of revenue and expenses and changes in capital and surplus. Depreciation is computed on the straight-line method over the estimated useful lives of the related assets, which range from five to forty years. Real estate investments are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable or exceeds fair value as determined by a recent appraisal. No losses were incurred for 2021 or 2020 as a result of this review.

Furniture and Equipment

Furniture and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method, based on the estimated useful lives of the related assets which range from three to five years. Upon retirement or disposal, the related asset and corresponding accumulated depreciation are removed from CHP's accounts and any gain or loss is reflected in operations.

Claims Unpaid and Unpaid Claims Adjustment Expenses

Claims unpaid includes an accrual for incurred but unpaid and unreported claims. The liability is based upon estimates of the eventual net cost of such services provided to members through the end of the year. Estimates of unpaid and unreported claims are based upon claims payment experience. The methods used in determining the liability are periodically reviewed and any

adjustments resulting from these revisions are reflected in current operations. The assumptions used are actuarially based and represent sufficient provision for all incurred but unpaid and unreported claims. Administrative costs to process outstanding claims are included in unpaid claims adjustment expenses.

Premium Deficiency Reserve

CHP lines of business were analyzed to determine if a premium deficiency reserve was required. There was no premium deficiency reserve established as of December 31, 2021 and 2020.

Revenue Recognition

All of CHP's individual and group contracts provide for the individual or group to be fully insured. Premiums for these contracts are billed on a monthly basis in advance of the coverage period and are recognized as revenue earned over the period of coverage. Fee-for-service income, investment income, and other revenue are recognized when earned.

Accounting for the Medicare Advantage and Part D Prescription Drug Program

CHP offers Medicare Advantage and Part D prescription drug insurance coverage under a contract with the Centers for Medicare & Medicaid Services ("CMS"). Premiums received in advance are recorded as unearned premiums. Costs for covered medical and prescription drugs are expensed as incurred. CMS utilizes a risk adjustment model which adjusts the payment for enrollees based on the underlying health condition of the beneficiaries. Under this model, member payments are adjusted in subsequent periods after CHP has submitted the final medical diagnosis information to CMS. CHP recorded receivables for current year risk of approximately \$2.0 million and \$3.3 million at December 31, 2021 and 2020, respectively. Risk adjustment payables for prior year activity were \$6.3 million and \$6.2 million at December 31, 2021 and 2020, respectively.

Under the Medicare Part D program, a risk sharing arrangement provides a risk corridor whereby the target amount (premiums received from members and CMS based on CHP's annual bid amount less administrative expenses) is compared to actual drug cost incurred during the contract year for individual Medicare members. Based upon the actual drug expense incurred a receivable from, or a payable to, CMS is recorded as an adjustment to premiums. Reconciliations for both individual and employer group Medicare members on the final risk sharing, low-income and reinsurance amounts are required annually. CHP recorded a net receivable of approximately \$7.5 million and \$4.4 million at December 31, 2021 and 2020, respectively.

As a Medicare plan sponsor, CHP administers the Medicare coverage gap subsidy, a discount from pharmaceutical manufacturers on brand drug costs to Medicare Part D enrollees exceeding their initial coverage limit until they qualify for catastrophic coverage. Amounts paid to pharmacies by CHP for this discount and reimbursed by the pharmaceutical manufacturers were \$12.6 million and \$11.3 million at December 31, 2021 and 2020, respectively.

Premiums and Consideration Receivables, Net

Premiums and other consideration receivables are reported net of an allowance for estimated uncollectible accounts of \$0.9 million and \$0.3 million at December 31, 2021 and 2020, respectively, which is calculated based upon historical activity and management's estimate of collectability. The carrying amount of CHP's receivables approximate fair values. None of the receivables are held for sale.

Health Care Receivables, Net

Health care receivables consist of pharmaceutical rebates and other receivables. Pharmaceutical rebates ("rebates") are generally volume discounts negotiated with drug manufacturers by CHP's

pharmacy benefit manager on behalf of the Company. Rebates are earned when a medication is dispensed to CHP's members. CHP estimates rebates based on historical rebate patterns and the arrangement between CHP and its pharmacy benefit management company. Rebates are recorded in health care receivables and as a reduction to hospital and medical expenses (Note 13).

Other receivables, primarily fee-for-service receivables, are reported net of an allowance for estimated uncollectible amounts.

Health Care Service Cost Recognition

CHP contracts with various health care providers for the provision of certain medical services to its members. CHP compensates these providers on a capitated and noncapitated basis. These expenses are included in hospital and medical expenses in the statutory statements of revenue and expenses and changes in capital and surplus.

Reinsurance Recognition

Reinsurance premiums are recorded as a reduction in premium income, and reinsurance recoveries are recorded as a reduction of hospital and medical expense when the eligible insured amount of the event can be estimated.

Malpractice Insurance

Malpractice insurance coverage is provided on a claims-made basis. The claims-made policies, which are subject to renewal on an annual basis, cover only claims made during the term of the policies. CHP is not aware of any claims that arose during the fiscal year that will be reported outside the policy renewal period. Accordingly, no provision for such claims was made at December 31, 2021 and 2020.

Use of Estimates and Assumptions

The accompanying financial statements have been prepared in conformity with the accounting practices prescribed or permitted by the OIR, which requires management to make certain estimates and assumptions that affect the reported amounts of admitted assets and liabilities and disclosure of contingent assets and liabilities at the date of the statutory financial statements, and the reported amounts of revenue and expenses during the reporting periods.

3. Tax Status

CHP has been granted an exemption from Federal income tax under the Internal Revenue Code, Section 501(c) (4). The Internal Revenue Code provides for taxation of certain unrelated business income. CHP had no significant unrelated business income in 2021 and 2020.

4. Investments

The amortized cost and fair value of investments for the years ended December 31, 2021 and 2020 is set forth in the following table.

| (in thousands of dollars) | A | mortized Cost | Un | Gross realized Gains | Uı | Gross rrealized Losses | | Fair Value |
|---|----|------------------|----|----------------------------|----|------------------------------|----|-----------------|
| 2021 | | | | | | | | |
| Debt securities | | | _ | | _ | () | _ | |
| U.S. Government and agencies | \$ | 343,929 | \$ | 3,680 | \$ | (3,460) | \$ | 344,149 |
| Corporate | | 104,926 | | 4,181 247 | | (541) | | 108,566 |
| Commercial mortgage-backed securities Other | | 7,830 43,889 | | 1,024 | | (33) (347) | | 8,044 44,566 |
| Total debt securities | - | | | | - | | - | |
| rotal debt securities | | 500,574 | | 9,132 | | (4,381) | | 505,325 |
| Equity securities | | 69,185 | | 45,404 | | (12) | | 114,577 |
| Total investments | \$ | 569,759 | \$ | 54,536 | \$ | (4,393) | \$ | 619,902 |
| 2020 | | | | | | | | |
| Debt securities | | | | | | | | |
| U.S. Government and agencies | \$ | 318,575 | \$ | 9,297 | \$ | (172) | \$ | 327,700 |
| Corporate | | 97,786 | | 8,393 | | (12) | | 106,167 |
| Commercial mortgage-backed securities | | 9,437 | | 598 | | (3) | | 10,032 |
| Other | | 39,515 | | 2,356 | | (19) | | 41,852 |
| Total debt securities | | 465,313 | | 20,644 | | (206) | | 485,751 |
| Equity securities | | 83,998 | | 40,270 | | | | 124,268 |
| Total investments | \$ | 549,311 | \$ | 60,914 | \$ | (206) | \$ | 610,019 |

The expected maturities of the debt securities are shown below. Expected maturities may differ from actual maturities due to call or prepayment provisions.

| | | 20 |)21 | | 2020 | | | | | | |
|---|----|--|-----|--|------|---------------------------------------|----|--|--|--|--|
| | Aı | mortized Cost | | Fair Value | Α | mortized Cost | | Fair Value | | | |
| Due in one year or less Due after one year through five years Due after five years through ten years Due after ten years | | 1,554 176,255 106,976 215,789 | \$ | 1,557 178,690 108,802 216,276 | \$ | 4,702 160,140 99,344 201,127 | \$ | 4,765 166,882 107,052 207,052 | | | |
| | \$ | 500,574 | \$ | 505,325 | \$ | 465,313 | \$ | 485,751 | | | |

The difference between amortized cost and fair value on these bonds totaled \$4.8 million and \$20.4 million as of December 31, 2021 and 2020, respectively. Proceeds from maturities of debt securities during 2021 and 2020 were \$1.4 million and \$1.8 million, respectively, and were included in Proceeds from investments sold or matured or repaid in the Statements of Cash Flows.

Proceeds from sales of total investments during 2021 and 2020 were \$319.9 million and \$360.0 million, respectively. Gross gains of \$16.3 million and \$9.3 million and gross losses of \$0.7 million and \$1.2 were realized on those sales in 2021 and 2020, respectively. There were no write downs for impairment during 2021 and 2020.

As of December 31, 2021 and 2020, investments with a decline in fair value below amortized cost were as follows, including the length of time of such decline:

| (in thousands of dollars) | One Year or Less | | | | | | | More Than One Year | | | | | | Total | | | | |
|---|------------------|---|----|---------------------------------------|----|---|----|---------------------------------|----|--------------------------------|----|---------------------------------|----|---|----|---------------------------------------|----|---|
| | | Fair Value | U | nrealized Loss | , | Amortized Cost | | Fair Value | Ur | realized Loss | Α | mortized Cost | | Fair Value | Ur | realized Loss | Α | mortized Cost |
| 2021 | • | 000.070 | • | (0.005) | • | 000 404 | • | 40.704 | • | (405) | • | 47.450 | • | 040.000 | • | (0.400) | • | 000 000 |
| US Government and agencies Corporate Commercial mortgage backed securities Other | \$ | 200,079 26,410 1,001 19,176 | \$ | (3,025) (439) (17) (252) | \$ | 203,104 26,849 1,018 19,428 | \$ | 16,721 1,776 470 2,464 | \$ | (435) (102) (16) (95) | \$ | 17,156 1,878 486 2,559 | \$ | 216,800 28,186 1,471 21,640 | \$ | (3,460) (541) (33) (347) | \$ | 220,260 28,727 1,504 21,987 |
| Total bonds | | 246,666 | | (3,733) | | 250,399 | | 21,431 | | (648) | | 22,079 | | 268,097 | | (4,381) | | 272,478 |
| Common stocks | _ | 2,213 | _ | (12) | _ | 2,225 | _ | | | | _ | | _ | 2,213 | _ | (12) | _ | 2,225 |
| | \$ | 248,879 | \$ | (3,745) | \$ | 252,624 | \$ | 21,431 | \$ | (648) | \$ | 22,079 | \$ | 270,310 | \$ | (4,393) | \$ | 274,703 |
| 2020 US Government and agencies Corporate Commercial mortgage backed securities Other Total bonds | \$ | 44,069 1,881 492 2,564 49,006 | \$ | (172) (12) (3) (19) (206) | \$ | 44,241 1,893 495 2,583 49,212 | \$ | - - - - | \$ | - - - - | \$ | - - - - | \$ | 44,069 1,881 492 2,564 49,006 | \$ | (172) (12) (3) (19) (206) | \$ | 44,241 1,893 495 2,583 49,212 |
| Common stocks | | 40,000 | | (200) | | 40,212 | | | | | | | | 40,000 | | (200) | | 70,212 |
| Common stocks | \$ | 49,006 | \$ | (206) | \$ | 49,212 | \$ | | \$ | | \$ | | \$ | 49,006 | \$ | (206) | \$ | 49,212 |

Investments with gross unrealized losses were not considered "other-than-temporarily" impaired due to the duration, low magnitude of the losses, or indications of recovery, and the conclusion that collection of contractual amounts due is probable. As of December 31, 2021, CHP does not intend to sell the securities with an unrealized loss position and it is not likely that CHP will be required to sell these securities before recovery of their amortized costs.

| | 2021 | 2020 |
|--|--------------|--------------|
| Investment income | | |
| Dividends and interest | \$ 17,510 | \$ 16,484 |
| Amortization of premium and discount on investments, net | (3,937) | (3,319) |
| Rent for owner occupied property | 4,403 | 4,321 |
| Total investment income | 17,976 | 17,486 |
| Less: Investment expenses | (497) | (461) |
| Net investment income earned | \$ 17,479 | \$ 17,025 |

5. Fair Value of Financial Instruments

The admitted assets and related fair values of all financial instruments, along with the levels within the fair value hierarchy used to determine the fair value measurements are as follows:

| (in thousands of dollars) | - | Admitted Assets | Level 1 | | Level 2 Level 3 | | | F | air Value | Not Practicable | | |
|---------------------------|----|--------------------|---------|---------|-----------------|---------|----|---|-----------|--------------------|----|---|
| 2021 | | | | | | | | | | | | |
| Bonds | \$ | 500,574 | \$ | 79,250 | \$ | 426,075 | \$ | - | \$ | 505,325 | \$ | - |
| Common stocks | | 114,577 | | 114,577 | | | | | | 114,577 | | |
| Total assets | \$ | 615,151 | \$ | 193,827 | \$ | 426,075 | \$ | - | \$ | 619,902 | \$ | - |
| 2020 | | | | | | | | | | | | |
| Bonds | \$ | 465,313 | \$ | 74,913 | \$ | 410,838 | \$ | - | \$ | 485,751 | \$ | - |
| Common stocks | | 124,268 | | 124,268 | | | | - | | 124,268 | | - |
| Total assets | \$ | 589,581 | \$ | 199,181 | \$ | 410,838 | \$ | | \$ | 610,019 | \$ | |

Transfers between levels are recognized at the beginning of the reporting period. There were no material transfers between levels in 2021 or 2020. There were no realized gains (losses) included in investment income and no unrealized gains and losses included in capital and surplus that required disclosure for the years ending December 31, 2021 and 2020.

6. Property and Equipment

Real estate investments, net at December 31, consist of the following:

| (in thousands of dollars) | | 2020 | | | | |
|--------------------------------------|----|--------------------|--------------------------|--|--|--|
| Property Accumulated depreciation | \$ | 60,829 (19,629) | \$ 60,547 (17,934) | | | |
| | \$ | 41,200 | \$ 42,613 | | | |

Furniture and equipment at December 31, consist of the following:

| (in thousands of dollars) | 2021 | | 2020 |
|---|-------------------------|------------|---------------------|
| Furniture and equipment Medical furniture and equipment | \$ 14,034 4,379 | \$ | 13,813 4,313 |
| | 18,413 | ' <u>-</u> | 18,126 |
| Accumulated depreciation Nonadmitted assets | (15,114) (3,299) | | (14,515) (3,611) |
| | \$ - | \$ | _ |

Depreciation expense during 2021 and 2020 was \$3.4 million and \$3.1 million, respectively. During 2021, CHP disposed of fully depreciated equipment that was deemed to be no longer in use.

Hospitalization

CHP has entered into contractual agreements with various hospitals to provide hospital services to CHP's members. In general these agreements automatically renew annually but can be terminated by sufficient notice.

Other Services

CHP has entered into contractual arrangements with certain physicians to provide laboratory and specialized services. In general these agreements automatically renew annually, but can be terminated by sufficient notice.

8. Claims Unpaid and Unpaid Claims Adjustment Expenses

Activity in claims unpaid and unpaid claims adjustment expenses is summarized as follows for the years ended December 31:

| (in thousands of dollars) | | 2020 | | | |
|---------------------------|----|---------|--------------|--|--|
| Balances at January 1, | \$ | 70,348 | \$ 67,499 | | |
| Incurred related to | | | | | |
| Current year | | 737,875 | 676,700 | | |
| Prior year | | (3,659) | (3,343) | | |
| Total incurred | | 734,216 | 673,357 | | |
| Paid related to | | | | | |
| Current year | | 665,600 | 606,352 | | |
| Prior year | | 66,689 | 64,156 | | |
| Total paid | | 732,289 | 670,508 | | |
| Balances at December 31, | \$ | 72,275 | \$ 70,348 | | |

The balances above are comprised of claims unpaid (\$71.6 million and \$69.6 million at December 31, 2021 and 2020, respectively), and unpaid claims adjustment expenses (\$0.7 million for December 31, 2021 and 2020).

Changes in the provision for claims unpaid and unpaid claims adjustment expenses attributable to insured events of the prior year are primarily the result of changes in estimates due to changes in medical cost trends that emerged when compared to historical levels. These estimates are reviewed regularly by management and periodically by an independent consulting actuary, and are adjusted as necessary as new information becomes known. Such adjustments are included in current operations.

9. Capital and Surplus

CHP is required by the OIR to maintain statutory capital and surplus not less than the greater of \$1.5 million, 10% of total liabilities, or 2% of annualized premium, which is \$19.0 million and \$18.1 million as of December 31, 2021 and 2020, respectively. CHP's capital and surplus exceeds OIR minimum statutory capital and surplus requirements by \$543.0 million and \$512.2 million as of December 31, 2021 and 2020, respectively.

Additionally, regulations require each HMO to ensure its statutory basis net income before taxes is not less than 2% of total revenues. If the HMO fails to meet the 2% requirement, a corrective action plan may be required. For 2021 and 2020, CHP met this required 2% net income threshold.

10. Employee Benefits

Pension Plan

CHP has a simplified employee pension plan (defined contribution plan) whereby contributions are made directly to employees' individual retirement accounts. Contributions, which are discretionary, are determined annually by CHP's management and allocated among participants in proportion to their eligible compensation during the plan year. All employees are eligible to participate and 100% vesting occurs after a six-month length of service requirement is met. Employer contributions during 2021 and 2020 were \$4.6 million and \$4.3 million respectively.

Postretirement Benefits Other Than Pensions

CHP adopted a postretirement benefit plan effective January 1, 2016 that provides health care insurance to retiring employees that meet certain age and service eligibility requirements. CHP recorded an accumulated postretirement benefit obligation liability of \$10.6 million and \$11.1 million as of December 31, 2021 and 2020, respectively.

The following table reflects the components of the benefit obligation at December 31, 2021 and 2020:

| (in thousands of dollars) | 2021 | | | 2020 | | |
|---------------------------------------|------|---------|----|--------|--|--|
| Change in benefit obligation | | | | | | |
| Benefit obligation, beginning of year | \$ | 11,141 | \$ | 9,065 | | |
| Service cost | | 457 | | 366 | | |
| Interest cost | | 288 | | 298 | | |
| Actuarial (gains) losses | | (1,259) | | 1,457 | | |
| Benefits paid | | (50) | | (45) | | |
| Benefit obligation, end of year | \$ | 10,577 | \$ | 11,141 | | |
| Net periodic benefit cost | | | | | | |
| Current service cost | \$ | 457 | \$ | 366 | | |
| Current interest cost | | 288 | | 298 | | |
| Amortization of prior service cost | | 821 | | 578 | | |
| Net periodic benefit cost | \$ | 1,566 | \$ | 1,242 | | |

CHP expects to amortize \$1.1 million of unrecognized prior service cost and \$0.4 million of unrecognized gain from accumulated postretirement benefit obligation into net periodic benefit cost during 2022. Actuarial losses (gains) are amortized using the straight-line method over the remaining service period of active employees expected to receive benefits from the plan.

Weighted-average assumptions used in determining the postretirement benefit obligation as of December 31, 2021 were:

| Discount rate | 2.9 % |
|--|-------|
| Initial 2022 post-Medicare medical trend | 5.0 % |
| Ultimate post-Medicare medical trend | 3.7 % |

Increasing the assumed medical trend by 1% would increase the accumulated benefit obligation at December 31, 2021 by \$2.8 million and increase the 2021 benefit expense by \$0.3 million. Decreasing medical trend by 1% would decrease the accumulated benefit obligation by \$2.1 million and decrease the 2021 benefit expense by \$0.2 million. The health care premiums will be

supported by CHP general assets as well as contributions received for eligible participants. The Company expects to receive minimal contributions to the postretirement health care plan during 2022.

The following table provides expected benefit payments for the years indicated:

(in thousands of dollars)

| 2022 | \$ 112 |
|-----------|-----------|
| 2023 | 132 |
| 2024 | 152 |
| 2025 | 169 |
| 2026 | 181 |
| 2027-2031 | 1,125 |

11. Reinsurance

CHP reinsures certain risks with another insurance company. The reinsurance agreement provides coverage for eligible inpatient hospital and transplant services in excess of a specific deductible of \$700,000 during 2021 and 2020 for each covered member. In addition, an aggregated specific deductible of \$425,000 applies for the policy year. The reinsurance policy has a maximum reinsurance coverage limit of \$3 million per member per year. If the reinsurance carrier fails to meet its commitment under the reinsurance agreements, CHP will be liable for the covered services. Total premiums paid during 2021 and 2020 were \$0.8 million and \$0.5 million, respectively. Reinsurance recoveries were \$1.6 million and \$0.3 million for 2021 and 2020, respectively. Amounts due to CHP under reinsurance agreements were \$1.6 million and \$0 at December 31, 2021 and 2020, respectively.

12. Commitments and Contingencies

Litigation

In the normal course of business, CHP is routinely involved is litigation with insured parties, beneficiaries, healthcare providers and others. In management's opinion, based upon the advice of external legal counsel, there is no litigation or unasserted claims outstanding that would have a material adverse effect on CHP's financial position, results of operations or cash flows.

Line of Credit

In June 2020, CHP amended its \$30 million secured Line of Credit Agreement with Capital City Bank, extending the terms until June 30, 2023. Shares in Vanguard Institutional Fund, maintained by the Bank of New York Mellon, secure the line at no less than an 80% loan to collateral value ratio. The agreement includes a variable floating rate of London Interbank Offered Rates ("LIBOR') plus 1.30% subject to a minimum interest rate of not less than 1.50% annually. If the Index becomes unavailable during the term of this loan, the lender will designate a 30-day Secured Overnight Financing Rate ("SOFR") as a substitute index. The interest rate was 1.50% at December 31, 2021 and 2020, respectively. As of December 31, 2021 and 2020 CHP had no borrowings outstanding and approximately \$11,000 and \$6,000 in interest payable, respectively, and no borrowings outstanding. The agreement governing borrowing includes covenants, which serve to ensure that CHP maintains adequate liquidity. CHP was in compliance with all debt covenants during each year and at December 31, 2021 and 2020.

Regulatory Environment

In March 2020, the President of the United States declared the outbreak of a novel coronavirus (COVID-19) a national emergency. In response, CHP issued premium waiver and refunds due to the reduced claim utilization tied to COVID-19. Premium rebates of \$2.3 million and \$20.4 million are recorded as a reduction to net premium income within the statutory statements of revenue and expenses and changes in capital and surplus for the years ended 2021 and 2020, respectively.

The Patient Protection and Affordable Care Act and The Health Care and Education Reconciliation Act of 2010 (collectively referred to as "Health Care Reform") transformed various aspects of, and increased regulation within, the U.S. health insurance industry. The following outlines specific provisions of Health Care Reform that impact CHP's financial position, results of operation and cash flow.

CHP follows SSAP 106, Affordable Care Act Section 9010 Assessment: Fees Paid to the Federal Government by Health Insurers ("health insurer fee") for these costs required by Health Care Reform. The health insurer fee is being levied based on a ratio of an insurer's net health insurance premiums written for the previous calendar year compared to the total U.S. health insurance market. The guidance specifies that a liability be estimated and fully recognized in the calendar year the fee is payable with a corresponding deferred asset once qualifying health insurance is provided. The deferred asset is amortized straight-line over the year and the liability is relieved when paid. Congress passed legislation in 2017 which imposed a moratorium for the 2019 calendar year for the collection of the insurer fee. CHP paid \$8.6 million in 2020 for the annual health insurer fee which was reflected in assessments and fees. In December 2019, Congress repealed the health insurer fee effective January 1, 2021.

Medical loss ratio ("MLR") regulation of Health Care Reform. Commercial fully insured health plans in the individual and group health insurance markets are required to spend at least 85% of premiums earned from large employer groups and 80% of premiums earned from individual and small group markets on a combination of medical care claims and activities to improve health care quality. The regulations require health plans to provide rebates to policy holders for any portion below these minimum thresholds. As of December 31, 2021 and 2020, CHP's MLR exceeded these requirements and therefore had no rebates due to policyholders. Medicare Advantage and Part D plans are also subject to the 85% requirement. CHP exceeded the MLR minimum threshold for the contract year 2021. A rebate reserve of \$1.3 million was recorded in 2020, and is expected to be paid in 2022.

As prescribed by Health Care Reform, the risk adjustment program provides for retrospective adjustments of revenue for certain ACA individual and small group plans. The risk adjustment program is designed such that payment to plans with higher relative risk is funded by transfers from plans with lower relative risk. CHP paid risk adjustment assessments of approximately \$9.2 million and \$5.9 million as of December 31, 2021 and 2020, respectively. Risk adjustment assessments and distributions are computed based on CHP's risk score versus the overall market risk score after applying adjustments. CHP records risk adjustment receivables and payables, gross, with an adjustment to premiums when the amounts are reasonably estimable and collection is reasonably assured. As of December 31, 2021 and 2020, risk adjustment receivables were approximately \$0 and \$4.1 million, respectively. Risk adjustment payables were approximately \$5.0 million and \$11.3 million as of December 31, 2021 and 2020 respectively.

The following table reflects activity related to the risk adjustment program prior year balances:

| (in thousands of dollars) | Ye | ing the Prior ar ss Written 2 (Payable) | _ | eceived or the Current \ Busin 3 | e Year on | | Prior Accrue Paym (Col 1 | d Less lents 1 - 3) | Acc F | Prior Year crued Less Payments Col 2 - 4) 6 (Payable) | To Price Balar | | To I | Prior Year alances 8 ayable) | Ref | Cumul Balance Prior Y (Col 1 +7 9 Receiv | from ears - 3 | Balan Prior (Co | ulative ice from r Years I 2 – 4 +8) 10 yable) |
|--|-------------|---|----|--|--------------|-----|-----------------------------------|---------------------------|----------|--|----------------|---|------|---------------------------------------|-----|--|---------------------|-----------------------|--|
| a. Permanent ACA Risk Adjustment Program | | | | | | | | | | | | | | | | | | | |
| Premium adjustments receivable | \$ 4,135 | \$ - | \$ | 4,137 | \$ | - | \$ | (2) | \$ | - | \$ | 2 | \$ | - | Α | \$ | - | \$ | - |
| Premium adjustments (payable) | - | (11,292) | | - | (9,2 | | | - | | (2,067) | | - | | 2,067 | В | | - | | - |
| Subtotal ACA Permanent Risk Adjustment Program | 4,135 | (11,292) | | 4,137 | (9,22 | 25) | | (2) | | (2,067) | | 2 | | 2,067 | | | - | | - |
| b. Transitional ACA Reinsurance Program | | | | | | | | | | | | | | | | | | | |
| Amounts recoverable for claims paid | - | - | | - | | - | | - | | - | | - | | - | | | - | | - |
| Amounts recoverable for claims unpaid (contra liability) | - | - | | - | | - | | - | | - | | - | | - | | | - | | - |
| Amounts receivable relating to uninsured plans | - | - | | - | | - | | - | | - | | - | | - | | | - | | - |
| Liabilities for contributions payable due to ACA | | | | | | | | | | | | | | | | | | | |
| Reinsurance – not reported as ceded premium | - | - | | - | | - | | - | | - | | - | | - | | | - | | - |
| Ceded reinsurance premiums payable | - | - | | | | - | | | | - | | - | | - | | | - | | - |
| Liability for amounts held under uninsured plans | - | - | | - | | - | | - | | - | | - | | - | | | - | | - |
| 7. Subtotal ACA Transitional Reinsurance Program | - | - | | | | - | | | | - | | - | | - | | | - | | - |
| c. Temporary ACA Risk Corridors Program | | | | | | | | | | | | | | | | | | | |
| Accrued retrospective premium | - | - | | | | - | | - | | - | | - | | - | | | - | | - |
| 2. Reserve for rate credits or policy experience rating refunds | - | - | | - | | - | | - | | - | | - | | - | | | - | | - |
| Subtotal ACA Risk Corridors Program | - | - | | | | - | | | | - | | - | | - | | | - | | - |
| d. Total for ACA Risk Sharing Provisions | \$ 4,135 | \$ (11,292) | \$ | 4,137 | \$ (9,22 | 25) | \$ | (2) | \$ | (2,067) | \$ | 2 | \$ | 2,067 | | \$ | - | \$ | - |
| Explanations of Adjustments | | | | | | | | | | | | | | | | | | | |

A. In 2021, CHP recorded an adjustment for a 2018 prior year settlement amount received.
 B. In 2021, CHP recorded an adjustments for 2014, 2015, 2016 and 2020 settlement years.

13. Pharmaceutical Rebate Receivable

At December 31, 2021 and 2020, respectively, the estimated pharmaceutical rebate receivables were \$11.2 million and \$9.0 million and were included in health care receivables, net in the statutory statement of admitted assets, liabilities and capital and surplus.

The activity related to pharmaceutical rebates for the years ended December 31, 2021, 2020, and 2019 by quarter is summarized as follows:

(in thousands of dollars)

| Quarter Ended | Ph Rel Rep Fi | Estimated Pharmacy Rebates as Reported on Financial Statements | | armacy ebates Billed Or herwise nfirmed | R Re Wi | Actual Rebates Received Within 90 Days of Billing | | Actual ebates eceived re Than O Days er Billing | Total Rebates Received |
|---|------------------------|--|----|---|---------------|--|----|--|--|
| 12/31/2021 9/30/2021 6/30/2021 3/31/2021 | \$ | 11,286 11,019 10,595 9,944 | \$ | - 10,986 10,543 10,324 | \$ | - - 9,021 8,522 | \$ | - - - 1,718 | \$ 9,021 10,240 |
| 12/31/2020 9/30/2020 6/30/2020 3/31/2020 | \$ | 9,018 9,050 8,718 7,989 | \$ | 9,418 9,041 8,839 8,533 | \$ | 8,116 7,509 7,520 8,397 | \$ | 1,285 1,473 1,360 145 | \$ 9,401 8,982 8,880 8,542 |
| 12/31/2019 9/30/2019 6/30/2019 3/31/2019 | \$ | 7,262 7,542 7,075 6,952 | \$ | 7,511 7,268 7,351 7,076 | \$ | 7,535 7,248 7,346 7,033 | \$ | 14 34 8 81 | \$ 7,549 7,282 7,354 7,114 |

14. Related Party Transactions

A certain CHP Board member is affiliated with Capital City Bank where CHP maintains a banking relationship, including a secured line of credit (Note 12). CHP paid bank service charges to this financial institution, net of interest received, of approximately \$42,000 and \$27,000 in 2021 and 2020, respectively. Interest paid to Capital City Bank was approximately \$68,000 and \$56,000 for 2021 and 2020, respectively. Total deposits maintained at this financial institution were \$4.2 million and \$2.3 million at December 31, 2021 and 2020, respectively. An entity partially owned by Capital City Bank leases office space from CHP. Payments received from this entity in 2021 and 2020 were approximately \$117,000 and \$19,000, respectively.

A certain CHP Board member is affiliated with Anway Long Group, a consulting firm that provides consulting services to CHP. For years 2021 and 2020, consulting fees paid to this group were \$33,000 and \$132,000, respectively.

CHP provides medical services to subscribers who are employed by certain companies who are managed or partially owned by certain members of CHP's board of directors. Total premiums paid to provide these services were approximately \$4.1 million and \$4.2 million in 2021 and 2020, respectively.

CHP maintains an agreement with Florida Blue whereby the companies combine to offer certain group purchasers a multiple option health care program, which includes consolidated billing, administrative services, and a provision for equalizing underwriting gains and losses on these particular groups. CHP recorded a liability related to this agreement of \$1.6 million and \$1.4 million at December 31, 2021 and 2020, respectively. CHP recorded \$2.1 million of premiums collected from these groups under the consolidated billing arrangement with Florida Blue in 2021 and 2020. Equalization underwriting losses of \$0.7 million and \$1.2 million were recorded for 2021 and 2020.

CHP also has agreements with Florida Blue and other related entities to provide certain administrative services. The total fees incurred under these agreements were \$0.3 million in 2021 and 2020, respectively.

CHP contracted with Prime Therapeutics, Inc. ("Prime"), a pharmacy benefits management company, to administer its pharmaceutical benefits program. Prime is a related party to CHP through common control by Florida Blue. CHP contracted with Prime Therapeutics, Inc. ("Prime"), a pharmacy benefits management company, to administer its pharmaceutical benefits program. Prime is a related party to CHP through common control by Florida Blue. For 2021 and 2020, CHP recorded pharmacy expense net of rebates recoveries of \$129.6 million and \$121.6 million, respectively, under this agreement. Total administration fees during 2021 and 2020 were \$2.3 million and \$2.0 million, respectively. CHP had a payable due to Prime of \$3.4 million and \$3.3 million at December 31, 2021 and 2020, respectively. As of December 31, 2021 and 2020, CHP had a receivable for rebates of \$24.0 million and \$19.6 million, respectively.

15. Subsequent Events

CHP has evaluated subsequent events through March 31, 2022, the date the financial statements were available for issuance. No such events were noted.



Capital Health Plan, Inc. Summary Investment Schedule December 31, 2021

| Investment Holdings Annual St | itted ported in the tatement | |
|--|------------------------------------|--|
| (in millions) Amount Percentage Amount | Percentage | |
| 1. Long-Term Bonds (Schedule D, Part 1): | | |
| 1.1 U.S. Governments \$ 123.2 18.3 % \$ 123.2 | 18.3 % | |
| 1.2 All Other Governments \$ 22.2 3.3 % \$ 22.2 | 3.3 % | |
| 1.3 U.S. States, Territiories, and Possessions, Guaranteed \$.3 0.0 % \$ 0.3 1.4 U.S. Political Subdivisions of States, Territories and Possessions. Guaranteed | 0.0 % | |
| 1.5 U.S. Special Revenue & Special Assessment Obligations, \$ 220.4 32.8 % \$ 220.4 etc. Non-Guaranteed | 32.8 % | |
| 1.6 Industrial and Miscellaneous \$ 133.4 19.9 % \$ 133.4 | 19.9 % | |
| 1.7 Hybrid Securities \$ 1.1 0.2 % \$ 1.1 1.8 Parent, Subsidiaries, and Affiliates \$ 1.9 SVO Identified Funds | 0.2 % | |
| 1.10 Bank Loans | | |
| 1.11 Total Long-Term Bonds <u>\$ 500.6</u> <u>74.5 %</u> <u>\$ 500.6</u> | 74.5 % | |
| Preferred Stocks (Schedule D, Part 2, Sections 1): Industrial and Misc. (Unaffiliated) Parent, Subsidiaries, and Affiliates | | |
| 2.3 Total Preferred Stocks 3. Common Stocks (Schedule D, Part 2, Sections 2): 3.1 Industrial and Misc. (Unaffiliated) Publicly Traded 3.2 Industrial and Misc. (Unaffiliated) Other 3.3 Parent, Subsidiaries, and Affiliates Publicly Traded 3.4 Parent, Subsidiaries, and Affiliates Other 3.5 Mutual Funds \$ 114.6 17.1 % \$ 114.6 3.6 Unit Investment Trusts | 17.1 % | |
| 3.7 Closed-End Funds | | |
| 3.8 Total Common Stocks \$ 114.6 17.1 % \$ 114.6 | 17.1 % | |
| 4. Mortgage Loans (Schedule B): 4.1 Farm Mortgages 4.2 Residential Mortgages 4.3 Commercial Mortgages 4.4 Mezzanine Real Estate Loans | | |
| 4.5 Total Mortgage Loans | | |
| 5. Real estate (Schedule A): 5.1 Properties Occupied by Company \$ 41.2 6.1 % \$ 41.2 5.2 Properties Held for Production of Income 5.3 Properties Held for Sale | 6.1 % | |
| 5.4 Total Real Estate \$ 41.2 6.1 % \$ 41.2 | 6.1 % | |
| | 0.1 70 | |
| 6. Cash, cash equivalents, and short term investments: 6.1 Cash (Schedule E, Part 1) \$ 5.0 0.7 % \$ 5.0 | 0.7 % | |
| 6.2 Cash Equivalents (Schedule E, Part 2) \$ 7.4 1.1 % \$ 7.4 | 1.1 % | |
| 6.3 Short-Term Investments (Schedule DA) | 1.1 70 | |
| 6.4 Total Cash, Cash Equivalents, and Short Term Investments \$ 12.4 1.8 % \$ 12.4 | 1.8 % | |
| 7. Contract Loans 8. Derivatives (Schedule DB) 9. Other Invested Assets (Schedule BA) | | |
| 10. Receivables for Securities \$ 3.1 0.5 % \$ 3.1 | 0.5 % | |
| 11. Securities Lending (Schedule DL Part 1) 12. Other Invested Assets \$ 0.1 0.0 % \$ - | 0.0 % | |
| 13. Total Invested Assets \$ 672.0 100.0 % \$ 671.9 | 100.0 % | |

(in millions)

- 1. Reporting entity's total admitted assets as reported on Page 2 of the annual statement: approximately \$705 million.
- 2. Ten largest exposures to a single issuer/borrower/investment

| | Issuer | Exposure | Ar | nount | Percent | | |
|------|---|----------|----|-------|---------|--|--|
| 2.01 | JPMorgan Chase & Company | Bonds | \$ | 4.0 | 0.6 % | | |
| 2.02 | Bank of America Corporation | Bonds | \$ | 3.9 | 0.5 % | | |
| 2.03 | International Bank for Reconstruction and Development | Bonds | \$ | 3.5 | 0.5 % | | |
| 2.04 | Morgan Stanley | Bonds | \$ | 2.8 | 0.4 % | | |
| 2.05 | Goldman Sachs Group, Inc. | Bonds | \$ | 2.6 | 0.4 % | | |
| 2.06 | Kreditanstalt Fuer Wiederaufba | Bonds | \$ | 2.1 | 0.3 % | | |
| 2.07 | Citigroup, Inc. | Bonds | \$ | 2.0 | 0.3 % | | |
| 2.08 | European Investment Bank | Bonds | \$ | 2.0 | 0.3 % | | |
| 2.09 | Asian Development Bank | Bonds | \$ | 1.9 | 0.3 % | | |
| 2.10 | Inter-American Development Bank | Bonds | \$ | 1.9 | 0.3 % | | |

3. Amounts and percentages of the reporting entity's total admitted assets held in bonds and preferred stocks by NAIC designation

| | | | | | Preferred | | | |
|------|----------|----|--------|---------|-----------|----|-------|---------|
| | Bonds | A | Amount | Percent | Stock | Aı | mount | Percent |
| 3.01 | NAIC - 1 | \$ | 436.2 | 61.9 % | P/RP - 1 | \$ | - | 0.0 % |
| 3.02 | NAIC - 2 | \$ | 64.4 | 9.1 % | P/RP - 2 | | | |
| 3.03 | NAIC - 3 | | | | P/RP - 3 | | | |
| 3.04 | NAIC - 4 | | | | P/RP - 4 | | | |
| 3.05 | NAIC - 5 | | | | P/RP - 5 | | | |
| 3.06 | NAIC - 6 | | | | P/RP - 6 | | | |

4. Assets held in foreign investments:

Are assets held in foreign investments less than 2.5% of the reporting entity's total admitted assets? ____ (yes) X (no)

If response to 4.01 above is yes, responses are not required for Interrogatories 5-10

| | Ar | nount | Percent |
|--|----|-------|---------|
| 4.02 Total admitted assets held in foreign investments | \$ | 87.3 | 12.4 % |
| 4.03 Foreign-currency-denominated investments | | | |
| 4.04 Insurance liabilities denominated in that same foreign currency | | | |

5. Aggregate foreign investment exposure categorized by NAIC sovereign designation:

| NAIC Sovereign Designation | Ar | mount | Percent |
|---|----|-------|---------|
| 5.01 Countries designated NAIC - 1 | \$ | 83.4 | 11.8 % |
| 5.02 Countries designated NAIC - 2 | \$ | 3.9 | 0.6 % |
| 5.03 Countries designated NAIC - 3 or below | | | |

(in millions)

6. Largest foreign investment exposures by country, categorized by the country's NAIC sovereign designation:

| | NAIC Sovereign Designation | Ar | nount | Percent |
|------|--|----|-------|---------|
| | Countries designated NAIC - 1 | | | |
| 6.01 | Japan | \$ | 13.5 | 1.9 % |
| 6.02 | Supranational Geographical Focus | \$ | 11.4 | 1.6 % |
| | Countries designated NAIC - 2 | | | |
| 6.03 | Italy | \$ | 1.3 | 0.2 % |
| 6.04 | Mexico | \$ | 1.0 | 0.1 % |
| | Countries designated NAIC - 3 or below | | | |
| 6.05 | | | | |

7. Aggregate unhedged foreign currency exposure:

| NAIC Sovereign Designation | Amount | Percent |
|----------------------------|---------|---------|
| 7.01 | \$ - | 0.0 % |

8. Aggregate unhedged foreign currency exposure categorized by NAIC sovereign designation:

| | NAIC Sovereign Designation | Amount | Percent |
|------|--|---------|---------|
| 8.01 | Countries designated NAIC - 1 | \$ - | 0.0 % |
| 8.02 | Countries designated NAIC - 2 | | |
| 8.03 | Countries designated NAIC - 3 or below | | |

Largest unhedged foreign currency exposures by country, categorized by the country's NAIC sovereign designation:

| | NAIC Sovereign Designation | Amount | Percent |
|------|--|---------|---------|
| 9.01 | Countries designated NAIC - 1 | \$ - | 0.0 % |
| 9.02 | Countries designated NAIC - 2 | | |
| 9.03 | Countries designated NAIC - 3 or below | | |

10. Ten largest non sovereign (i.e. nongovernmental) foreign issues:

| Issuer | NAIC Designation | - | Amount | Percent |
|---|------------------|----|--------|---------|
| 10.01 International Bank for Reconstruction and Development | 1 | \$ | 3.5 | 0.5 % |
| 10.02 Kreditanstalt Fuer Wiederaufba | 1 | \$ | 2.1 | 0.3 % |
| 10.03 European Investment Bank | 1 | \$ | 2.0 | 0.3 % |
| 10.04 Asian Development Bank | 1 | \$ | 1.9 | 0.3 % |
| 10.05 Inter-American Development Bank | 1 | \$ | 1.9 | 0.3 % |
| 10.06 HSBC Holdings, PLC | 1 | \$ | 1.8 | 0.3 % |
| 10.07 Israel, State of (Government) | 1 | \$ | 1.1 | 0.1 % |
| 10.08 Japan Bank for International Cooperation | 1 | \$ | 1.0 | 0.1 % |
| 10.09 Mexico (United Mexican States) (Government) | 2 | \$ | 1.0 | 0.1 % |
| 10.10 Bank of Nova Scotia | 1 | \$ | .9 | 0.1 % |

11. Amounts and percentages of the reporting entity's total admitted assets held in Canadian investments and unhedged Canadian currency exposure:

(in millions)

- 11.01 Are assets held in Canadian investments less than 2.5% of the reporting entity's total admitted assets? X (yes) __(no) If response to 11.01 is yes, detail is not required for the remainder of Interrogatory 11.
- 12. Report aggregate amounts and percentages of the reporting entity's total admitted assets held in investments with contractual sales restrictions.

Are assets held in investments with contractual sales restrictions less than 2.5% of the reporting entity's total admitted assets? X (yes) __(no)

If response to 12.01 is yes, responses are not required for the remainder of Interrogatory 12.

- 13. Amounts and percentages of admitted assets held in the ten largest equity interests:
 - 13.01 Are assets held in equity interest less than 2.5% of the reporting entity's total admitted assets? __(yes) X (no)

If response to 13.01 is yes, responses are not required for the remainder of Interrogatory 13.

| Assets held in equity interests | Issuer | Ar | mount | Percent |
|---------------------------------|-------------------------------------|----|-------|---------|
| 13.02 | Vanguard Institutional Index Fund | \$ | 69.2 | 9.8 % |
| 13.03 | Fidelity Spartan International Fund | \$ | 45.4 | 6.4 % |

- 14. Amounts and percentages of the reporting entity's total admitted assets held in non-affiliated, privately placed equities:
 - 14.01 Are assets held in non-affiliated, privately placed equities less than 2.5% of the reporting entity's total admitted assets? X (yes) ____(no)

If response to 14.01 above is yes, responses are not required for the remainder of Interrogatory 14.

- 15. Amounts and percentages of the reporting entity's total admitted assets held in general partnership interests:
 - 15.01 Are assets held in general partnership interests less than 2.5% of the reporting entity's total admitted assets? X (yes) __(no)

If response to 15.01 above is yes, responses are not required for the remainder of Interrogatory 15.

- 16. Amounts and percentages of the reporting entity's total admitted assets held in mortgage loans:
 - 16.01 Are mortgage loans reported in Schedule B less than 2.5% of the reporting entity's total admitted assets? X (yes) __(no)

If response to 16.01 above is yes, responses are not required for the remainder of Interrogatory 16 and Interrogatory 17.

17. Aggregate mortgage loans having the following loan-to-value ratios as determined from the most current appraisal as of the annual statement date:

(in millions)

- 18. Amounts and percentages of the reporting entity's total admitted assets held in each of the five largest investments in real estate:
 - 18.01 Are assets held in real estate reported in less than 2.5% of the reporting entity's total admitted assets? __(yes) X (no)

If response to 18.01 above is yes, responses are not required for the remainder of Interrogatory 18.

| Description | Ar | nount | Percent |
|--|----|-------|---------|
| 18.02 Metropolitan Building - Tallahassee, FL | \$ | 25.0 | 3.6 % |
| 18.03 Raymond Diehl Building - Tallahassee, FL | \$ | 7.6 | 1.1 % |
| 18.04 Governor's Square Building - Tallahassee, FL | \$ | 4.9 | 0.7 % |
| 18.05 Centerville Building - Tallahassee, FL | \$ | 2.8 | 0.4 % |
| 18.06 Capital Oaks Building - Tallahassee, FL | \$ | .8 | 0.1 % |

- Report aggregate amounts and percentages of the reporting entity's total admitted assets held in investments held in mezzanine real estate loans:
 - 19.01 Are assets held in investments held in mezzanine real estate loans less than 2.5% of the reporting entity's total admitted assets? X (yes) __(no)

If response to 19.01 is yes, responses are not required for the remainder of Interrogatory 19.

20. Amounts and percentages of the reporting entity's total admitted assets subject to the following types of agreements:

| | | At Year | -End | | | \t En | d of Each | Qua | ırter | | |
|---|-----|---------|---------|----|--------|-------|-----------|-----|-------|---------|---|
| NAIC Sovereign Designation | Amo | unt | Percent | 1 | st Qtr | | 2nd Qtr | | | 3rd Qtr | |
| 20.01 Securities lending agreements (do not include assets held | | | | | | | | | | | |
| as collateral for such transactions) | \$ | - | 0.0 % | \$ | - | \$ | ; | - | \$ | | - |
| 20.02 Repurchase agreements | | | | | | | | | | | |

- 20.03 Reverse repurchase agreements
- 20.04 Dollar repurchase agreements
- 20.05 Dollar reverse repurchase agreements
- Amounts and percentages of the reporting entity's total admitted assets for warrants not attached to other financial instruments, options, caps, and floors:

| | Ow | ned | Wri | tten |
|----------------------------|--------|---------|--------|---------|
| NAIC Sovereign Designation | Amount | Percent | Amount | Percent |
| 21.01 Hedging | \$ - | 0 % | \$ - | 0 % |
| 21.02 Income generation | | | | |
| 21.03 Other | | | | |

(in millions)

22. Amounts and percentages of the reporting entity's total admitted assets of potential exposure for collars, swaps, and forwards

| | | At Yea | r-End | | At | End | l of Each Qu | arter | | |
|-------------------------|----|--------|---------|---------|----|-----|--------------|-------|---------|---|
| Description | Am | ount | Percent | 1st Qtr | | | 2nd Qtr | | 3rd Qtr | |
| 22.01 Hedging | \$ | - | 0 % | \$ | - | \$ | - | \$ | | - |
| 22.02 Income generation | | | | | | | | | | |
| 22.03 Replications | | | | | | | | | | |
| 22.04 Other | | | | | | | | | | |

23. Amounts and percentages of the reporting entity's total admitted assets of potential exposure for futures contracts:

| | | At Year | r-End | | At | End of I | Each Qua | rter | | |
|-------------------------|----|---------|---------|----|-------|----------|----------|------|---------|---|
| Description | Am | ount | Percent | 1s | t Qtr | 2n | d Qtr | | 3rd Qtr | |
| 23.01 Hedging | \$ | - | 0 % | \$ | - | \$ | - | \$ | | - |
| 23.02 Income generation | | | | | | | | | | |
| 23.03 Replications | | | | | | | | | | |
| 23.04 Other | | | | | | | | | | |

Capital Health Plan, Inc. Supplemental Schedule of Reinsurance Disclosures Year Ended December 31, 2021

The following information regarding reinsurance contracts is presented to satisfy the disclosure requirements in SSAP No. 61R, *Life, Deposit-Type and Accident and Health Reinsurance*, which apply to reinsurance contract entered into, renewed or amended on or after January 1, 1996.

| 1. | Has the Company reinsured any risk with any other entity under a reinsurance contract (or multiple contracts with the same reinsurer or its affiliates) that is subject to Appendix A-791, Life and health Reinsurance Agreements and includes a provision that limits the reinsurer's assumptions of significant |
|----|--|
| | risks identified in Appendix A-791? |
| | Example of risk-limiting features include provisions such as a deductible, a loss ratio corridor, a loss cap, an aggregate limit or similar effect. |
| | Yes ☐ No ☒ |
| | If yes, indicate the number of reinsurance contract to which such provisions apply: |
| | If yes, indicate if deposit accounting was applied for all contracts subject to Appendix A-791 that limit significant risks. |
| | Yes ☐ No ☐ N/A ☒ |
| 2. | Has the Company reinsured any risk with any other entity under a reinsurance contract (or multiple contracts with the same reinsurer or its affiliates) that is not subject to Appendix A-791, for which reinsurance accounting was applied and includes a provision that limits the reinsurer's assumption of risk? |
| | Example of risk-limiting features include provisions such as a deductible, a loss ratio corridor, a loss cap, an aggregate limit or other provisions that result in similar effects. |
| | Yes ☐ No ☒ |
| | If yes, indicate the number of reinsurance contract to which such provisions apply: |
| | If yes, indicate whether the reinsurance credit was reduced for the risk-limiting features. |
| | Yes ☐ No ☐ N/A ☒ |
| 3. | Does the Company have any reinsurance contracts (other than reinsurance contracts with a federal or state facility) that contain one or more of the following features which result in delays in payment in form or in fact: |
| | a. Provision that permit the reporting of losses to be made less frequently than quarterly; |
| | b. Provisions that permit settlements to be made less frequently than quarterly; |
| | c. Provisions that permit payments due from the reinsurer to not be made in cash within ninety (90) days to the settlement date (unless there is no activity during period); or |
| | d. The existence of payment schedules, accumulating retentions from multiple years, or any features inherently designed to delay timing of the reimbursement to the ceding entity. |
| | Yes ☐ No ☒ |
| | |

Capital Health Plan, Inc. Supplemental Schedule of Reinsurance Disclosures Year Ended December 31, 2021

4. Has the Company reflected reinsurance accounting credit for any contracts that are not subject to Appendix A-791 and not yearly renewable term reinsurance, which meet the risk transfer requirements of SSAP No. 61R?

| Type of Contract | Response: | Identify reinsurance contact(s): | Has the insured event(s) triggering contract coverage been recognized? |
|---|------------|-------------------------------------|--|
| Assumption reinsurance – new for the reporting period | Yes ☐ No ⊠ | | N/A |
| Non-proportional reinsurance does not result in significant surplus relief | Yes ☐ No ⊠ | | N/A |

| 5. | . Has the Company ceded any risk in a reinsurance agreement that is not subject to Appendix A-791 and not yearly renewable term reinsurance, under any reinsurance contract (or multiple contracts with the same reinsurer or its affiliates) during the period covered by the financial statements, and either: | | | | | | |
|----|--|--|--|--|--|--|--|
| | a. Accounted for that contract as reinsurance under statutory accounting principles (SAP) and as a deposit under generally accepted accounting principles (GAAP); or | | | | | | |
| | Yes ☐ No ☐ N/A ☒ | | | | | | |
| | b. Accounted for that contract as reinsurance under GAAP and as a deposit under SAP? | | | | | | |
| | Yes ☐ No ☐ N/A ☒ | | | | | | |
| | If the answer to item (a) or ite differences to explain why the | | | | | | |
| | Yes 🗌 No 🗌 N/A | | | | | | |
| | | | | | | | |